Theranexus 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   1 Trial   3 News 
  • ||||||||||  Review, Journal:  Recently Approved and Upcoming Treatments for Narcolepsy. (Pubmed Central) -  Jun 10, 2021   
    Several new agents are being developed and tested as potential treatments for EDS and cataplexy associated with narcolepsy; these agents include novel oxybate formulations (once-nightly [FT218]; low sodium [JZP-258]), a selective norepinephrine reuptake inhibitor (AXS-12), and a product combining modafinil and an astroglial connexin inhibitor (THN102). This review summarises the mechanisms of action, pharmacokinetics, efficacy, and safety/tolerability of recently approved and emerging treatments for narcolepsy.
  • ||||||||||  modafinil / Generic mfg.
    Review, Journal:  Advances in treatment of narcolepsy (Pubmed Central) -  Oct 23, 2020   
    These new drugs include new hydroxybutyrate preparations (controlled release sodium hydroxybutyrate FT218, low sodium hydroxybutyrate JZP-258), selective norepinephrine reuptake inhibitor (AXS-12), and modafinil combined with astroglial junction protein inhibitor (THN102). This paper reviews the recently approved drugs and potential treatments for narcolepsy.
  • ||||||||||  donepezil / Generic mfg., donepezil/mefloquine (THN 201) / Theranexus
    Clinical, Journal:  Pharmaco-fUS for Characterizing Drugs for Alzheimer's Disease - The Case of THN201, a Drug Combination of Donepezil Plus Mefloquine. (Pubmed Central) -  Sep 11, 2020   
    As an example, we showed that although administration of donepezil or mefloquine alone at low dose had only very limited effects on the signal compared to the baseline, their combination produced marked hemodynamic effects in the hippocampus, in line with previously published behavioral data demonstrating a synergic interaction between both drugs. Thus, the present study provides new perspectives, (i) through the use of pharmaco-fUS, a new non-clinical imaging modality, to move forward drug discovery in AD and (ii) by the profiling of two drug treatments on brain dynamics, one used in AD: donepezil, and the other in development: donepezil combined with mefloquine (THN201) as a modulator of astrocyte network.
  • ||||||||||  donepezil / Generic mfg., donepezil/mefloquine (THN 201) / Theranexus, mefloquine / Generic mfg.
    Clinical, Journal:  Efficacy of THN201, a Combination of Donepezil and Mefloquine, to Reverse Neurocognitive Deficits in Alzheimer's Disease. (Pubmed Central) -  Jul 3, 2020   
    In parallel, we determined that MEF potentiated DPZ-induced release of acetylcholine in hippocampus. Finally, local genetic silencing of astrocyte Cxs in the hippocampus was also found to enhance the procognitive effect of DPZ, pointing out the importance of Cx-dependent astrocyte networks in memory processes.
  • ||||||||||  flecainide/modafinil (THN102) / Theranexus
    Trial completion date, Trial primary completion date:  Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness (clinicaltrials.gov) -  Sep 10, 2019   
    P2,  N=60, Recruiting, 
    Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Oct 2019 Trial completion date: Oct 2019 --> Feb 2020 | Trial primary completion date: Sep 2019 --> Dec 2019
  • ||||||||||  flecainide/modafinil (THN102) / Theranexus
    Journal:  Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination. (Pubmed Central) -  Jul 19, 2019   
    These regions, highly involved in the regulation of sleep-wake cycle, emotions, and cognitive functions were hence quantitatively modulated by THN102. Data presented here provide the first evidence of a regional brain activation induced by THN102, currently being tested in a phase II clinical trial in narcoleptic patients.
  • ||||||||||  flecainide/modafinil (THN102) / Theranexus
    Trial completion:  Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients (clinicaltrials.gov) -  May 21, 2019   
    P2,  N=51, Completed, 
    Data presented here provide the first evidence of a regional brain activation induced by THN102, currently being tested in a phase II clinical trial in narcoleptic patients. Recruiting --> Completed
  • ||||||||||  flecainide/modafinil (THN102) / Theranexus
    Trial completion date, Trial primary completion date:  Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients (clinicaltrials.gov) -  Jun 25, 2018   
    P2,  N=48, Recruiting, 
    Trial primary completion date: Mar 2019 --> Sep 2019 Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: May 2018 --> Sep 2018
  • ||||||||||  flecainide/modafinil (THN102) / Theranexus
    Enrollment open:  Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients (clinicaltrials.gov) -  Nov 10, 2016   
    P2,  N=48, Recruiting, 
    Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: May 2018 --> Sep 2018 Not yet recruiting --> Recruiting